Does the media prefer LONA or DARE?

In the previous week, Dare Bioscience had 3 more articles in the media than Athira Pharma. MarketBeat recorded 10 mentions for Dare Bioscience and 7 mentions for Athira Pharma. Dare Bioscience's average media sentiment score of 0.78 beat Athira Pharma's score of 0.73 indicating that Dare Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Athira Pharma 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dare Bioscience 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer DARE or SPRO?

Dare Bioscience presently has a consensus target price of $10.00, indicating a potential upside of 975.27%. Given Dare Bioscience's stronger consensus rating and higher probable upside, research analysts plainly believe Dare Bioscience is more favorable than Spero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dare Bioscience 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Spero Therapeutics 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor DARE or SPRO?

In the previous week, Dare Bioscience had 1 more articles in the media than Spero Therapeutics. MarketBeat recorded 10 mentions for Dare Bioscience and 9 mentions for Spero Therapeutics. Spero Therapeutics' average media sentiment score of 0.87 beat Dare Bioscience's score of 0.78 indicating that Spero Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dare Bioscience 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spero Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, DARE or TLPH?

Dare Bioscience has higher revenue and earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than Dare Bioscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dare Bioscience $1.03M 13.62 -$13.40M -$0.95 N/A Talphera $30K 2,127.90 -$14.29M -$0.31 N/A

Is DARE or TLPH more profitable?

Talphera has a net margin of 0.00% compared to Dare Bioscience's net margin of -803.80%. Talphera's return on equity of -87.28% beat Dare Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Dare Bioscience -803.80% -512.31% -36.20% Talphera N/A -87.28% -51.36%

Does the media favor DARE or TLPH?

In the previous week, Talphera had 5 more articles in the media than Dare Bioscience. MarketBeat recorded 15 mentions for Talphera and 10 mentions for Dare Bioscience. Dare Bioscience's average media sentiment score of 0.78 beat Talphera's score of 0.59 indicating that Dare Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dare Bioscience 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Talphera 1 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, CLNN or DARE?

Dare Bioscience has higher revenue and earnings than Clene. Clene is trading at a lower price-to-earnings ratio than Dare Bioscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Clene $200K 264.55 -$26.17M -$3.20 N/A Dare Bioscience $1.03M 13.62 -$13.40M -$0.95 N/A

Is CLNN or DARE more profitable?

Dare Bioscience has a net margin of -803.80% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat Dare Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Clene -25,009.70% N/A -137.98% Dare Bioscience -803.80% -512.31% -36.20%

Does the media prefer CLNN or DARE?

In the previous week, Dare Bioscience had 2 more articles in the media than Clene. MarketBeat recorded 10 mentions for Dare Bioscience and 8 mentions for Clene. Dare Bioscience's average media sentiment score of 0.78 beat Clene's score of 0.53 indicating that Dare Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Clene 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Dare Bioscience 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is DARE or CING more profitable?

Cingulate has a net margin of 0.00% compared to Dare Bioscience's net margin of -803.80%. Cingulate's return on equity of -347.67% beat Dare Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Dare Bioscience -803.80% -512.31% -36.20% Cingulate N/A -347.67% -153.02%

Does the media favor DARE or CING?

In the previous week, Dare Bioscience had 3 more articles in the media than Cingulate. MarketBeat recorded 10 mentions for Dare Bioscience and 7 mentions for Cingulate. Cingulate's average media sentiment score of 1.16 beat Dare Bioscience's score of 0.78 indicating that Cingulate is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dare Bioscience 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cingulate 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Trading of Dare Bioscience was halted at 12:45 PM EST due to "LULD Pause".

Dare Bioscience (DARE) Competitors

$0.93 -0.44 (-32.12%)

Closing price 04:00 PM Eastern

Extended Trading

$0.90 -0.03 (-3.33%)

As of 08:00 PM Eastern

Compare

DARE vs. LONA, SPRO, TLPH, CLNN, and CING

Should you buy Dare Bioscience stock or one of its competitors? Dare Bioscience's main competitors and comparable companies include Athira Pharma (LONA), Spero Therapeutics (SPRO), Talphera (TLPH), Clene (CLNN), and Cingulate (CING). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Dare Bioscience compare to Athira Pharma?

Athira Pharma (NASDAQ:LONA) and Dare Bioscience (NASDAQ:DARE) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Athira Pharma has a net margin of 0.00% compared to Dare Bioscience's net margin of -803.80%. Athira Pharma's return on equity of -381.01% beat Dare Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-381.01%	-225.74%
Dare Bioscience	-803.80%	-512.31%	-36.20%

Dare Bioscience has higher revenue and earnings than Athira Pharma. Athira Pharma is trading at a lower price-to-earnings ratio than Dare Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$5.21	N/A
Dare Bioscience	$1.03M	13.62	-$13.40M	-$0.95	N/A

Athira Pharma has a beta of 2.04, indicating that its stock price is 104% more volatile than the broader market. Comparatively, Dare Bioscience has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market.

Athira Pharma presently has a consensus price target of $16.00, indicating a potential upside of 100.50%. Dare Bioscience has a consensus price target of $10.00, indicating a potential upside of 975.27%. Given Dare Bioscience's higher probable upside, analysts clearly believe Dare Bioscience is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

57.1% of Athira Pharma shares are owned by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are owned by institutional investors. 25.7% of Athira Pharma shares are owned by insiders. Comparatively, 4.1% of Dare Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Dare Bioscience had 3 more articles in the media than Athira Pharma. MarketBeat recorded 10 mentions for Dare Bioscience and 7 mentions for Athira Pharma. Dare Bioscience's average media sentiment score of 0.78 beat Athira Pharma's score of 0.73 indicating that Dare Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Athira Pharma	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dare Bioscience	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Dare Bioscience beats Athira Pharma on 8 of the 15 factors compared between the two stocks.

How does Dare Bioscience compare to Spero Therapeutics?

Dare Bioscience (NASDAQ:DARE) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

Spero Therapeutics has a net margin of 24.90% compared to Dare Bioscience's net margin of -803.80%. Spero Therapeutics' return on equity of 16.17% beat Dare Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	-803.80%	-512.31%	-36.20%
Spero Therapeutics	24.90%	16.17%	12.57%

Dare Bioscience presently has a consensus target price of $10.00, indicating a potential upside of 975.27%. Given Dare Bioscience's stronger consensus rating and higher probable upside, research analysts plainly believe Dare Bioscience is more favorable than Spero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Spero Therapeutics	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

6.7% of Dare Bioscience shares are owned by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are owned by institutional investors. 4.1% of Dare Bioscience shares are owned by insiders. Comparatively, 2.9% of Spero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Spero Therapeutics has higher revenue and earnings than Dare Bioscience. Dare Bioscience is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.03M	13.62	-$13.40M	-$0.95	N/A
Spero Therapeutics	$42.96M	1.66	$8.57M	$0.11	11.18

In the previous week, Dare Bioscience had 1 more articles in the media than Spero Therapeutics. MarketBeat recorded 10 mentions for Dare Bioscience and 9 mentions for Spero Therapeutics. Spero Therapeutics' average media sentiment score of 0.87 beat Dare Bioscience's score of 0.78 indicating that Spero Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dare Bioscience	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spero Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dare Bioscience has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market. Comparatively, Spero Therapeutics has a beta of 1.55, suggesting that its share price is 55% more volatile than the broader market.

Summary

Spero Therapeutics beats Dare Bioscience on 10 of the 16 factors compared between the two stocks.

How does Dare Bioscience compare to Talphera?

Dare Bioscience (NASDAQ:DARE) and Talphera (NASDAQ:TLPH) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Talphera has a net margin of 0.00% compared to Dare Bioscience's net margin of -803.80%. Talphera's return on equity of -87.28% beat Dare Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	-803.80%	-512.31%	-36.20%
Talphera	N/A	-87.28%	-51.36%

Dare Bioscience presently has a consensus target price of $10.00, suggesting a potential upside of 975.27%. Talphera has a consensus target price of $3.00, suggesting a potential upside of 143.90%. Given Dare Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Dare Bioscience is more favorable than Talphera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Dare Bioscience has higher revenue and earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than Dare Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.03M	13.62	-$13.40M	-$0.95	N/A
Talphera	$30K	2,127.90	-$14.29M	-$0.31	N/A

Dare Bioscience has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market. Comparatively, Talphera has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market.

In the previous week, Talphera had 5 more articles in the media than Dare Bioscience. MarketBeat recorded 15 mentions for Talphera and 10 mentions for Dare Bioscience. Dare Bioscience's average media sentiment score of 0.78 beat Talphera's score of 0.59 indicating that Dare Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dare Bioscience	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Talphera	1 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

6.7% of Dare Bioscience shares are held by institutional investors. Comparatively, 37.7% of Talphera shares are held by institutional investors. 4.1% of Dare Bioscience shares are held by insiders. Comparatively, 3.5% of Talphera shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Dare Bioscience beats Talphera on 9 of the 15 factors compared between the two stocks.

How does Dare Bioscience compare to Clene?

Clene (NASDAQ:CLNN) and Dare Bioscience (NASDAQ:DARE) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

23.3% of Clene shares are owned by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are owned by institutional investors. 28.3% of Clene shares are owned by company insiders. Comparatively, 4.1% of Dare Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Clene has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market. Comparatively, Dare Bioscience has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market.

Dare Bioscience has a net margin of -803.80% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat Dare Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Clene	-25,009.70%	N/A	-137.98%
Dare Bioscience	-803.80%	-512.31%	-36.20%

In the previous week, Dare Bioscience had 2 more articles in the media than Clene. MarketBeat recorded 10 mentions for Dare Bioscience and 8 mentions for Clene. Dare Bioscience's average media sentiment score of 0.78 beat Clene's score of 0.53 indicating that Dare Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Clene	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Dare Bioscience	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Clene presently has a consensus target price of $33.25, indicating a potential upside of 703.14%. Dare Bioscience has a consensus target price of $10.00, indicating a potential upside of 975.27%. Given Dare Bioscience's higher possible upside, analysts clearly believe Dare Bioscience is more favorable than Clene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Dare Bioscience has higher revenue and earnings than Clene. Clene is trading at a lower price-to-earnings ratio than Dare Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clene	$200K	264.55	-$26.17M	-$3.20	N/A
Dare Bioscience	$1.03M	13.62	-$13.40M	-$0.95	N/A

Summary

Dare Bioscience beats Clene on 9 of the 16 factors compared between the two stocks.

How does Dare Bioscience compare to Cingulate?

Dare Bioscience (NASDAQ:DARE) and Cingulate (NASDAQ:CING) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

6.7% of Dare Bioscience shares are held by institutional investors. Comparatively, 41.3% of Cingulate shares are held by institutional investors. 4.1% of Dare Bioscience shares are held by company insiders. Comparatively, 5.3% of Cingulate shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Dare Bioscience has higher revenue and earnings than Cingulate. Cingulate is trading at a lower price-to-earnings ratio than Dare Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.03M	13.62	-$13.40M	-$0.95	N/A
Cingulate	N/A	N/A	-$22.45M	-$4.23	N/A

In the previous week, Dare Bioscience had 3 more articles in the media than Cingulate. MarketBeat recorded 10 mentions for Dare Bioscience and 7 mentions for Cingulate. Cingulate's average media sentiment score of 1.16 beat Dare Bioscience's score of 0.78 indicating that Cingulate is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dare Bioscience	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cingulate	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dare Bioscience has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market. Comparatively, Cingulate has a beta of -0.9, meaning that its share price is 190% less volatile than the broader market.

Dare Bioscience currently has a consensus price target of $10.00, suggesting a potential upside of 975.27%. Cingulate has a consensus price target of $27.33, suggesting a potential upside of 437.00%. Given Dare Bioscience's higher possible upside, research analysts clearly believe Dare Bioscience is more favorable than Cingulate.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Cingulate has a net margin of 0.00% compared to Dare Bioscience's net margin of -803.80%. Cingulate's return on equity of -347.67% beat Dare Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	-803.80%	-512.31%	-36.20%
Cingulate	N/A	-347.67%	-153.02%

Summary

Dare Bioscience beats Cingulate on 8 of the 15 factors compared between the two stocks.

Get Dare Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DARE vs. The Competition

Export

Metric	Dare Bioscience	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$20.66M	$11.89B	$7.06B	$13.10B
Dividend Yield	N/A	2.70%	2.57%	10.45%
P/E Ratio	-1.33	775.15	269.06	25.28
Price / Sales	13.62	743.86	602.43	91.76
Price / Cash	N/A	66.45	70.48	50.90
Price / Book	4.65	11.60	12.91	6.24
Net Income	-$13.40M	$2.77B	$3.45B	$347.60M
7 Day Performance	-33.57%	0.17%	1.12%	1.07%
1 Month Performance	-55.07%	0.35%	1.79%	1.03%
1 Year Performance	-55.07%	161.52%	67.69%	20.77%

Dare Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DARE Dare Bioscience	2.4945 of 5 stars	$0.93 -32.1%	$10.00 +975.3%	-35.1%	$20.66M	$1.03M	N/A	30	News Coverage Earnings Report Gap Up Trading Halted High Trading Volume
LONA Athira Pharma	3.8009 of 5 stars	$7.66 +2.5%	$16.00 +108.9%	N/A	$71.93M	N/A	N/A	40	News Coverage Earnings Report
SPRO Spero Therapeutics	1.9916 of 5 stars	$1.23 +7.0%	N/A	-35.8%	$71.22M	$66.80M	5.13	150	News Coverage Earnings Report Analyst Upgrade
TLPH Talphera	3.0554 of 5 stars	$1.36 +2.3%	$3.00 +120.6%	+179.8%	$70.58M	$1K	N/A	19	News Coverage Earnings Report Analyst Forecast Analyst Revision
CLNN Clene	1.9174 of 5 stars	$5.28 +1.7%	$33.25 +529.7%	+14.8%	$67.48M	$200K	N/A	100	News Coverage Earnings Report Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DARE) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dare Bioscience (DARE) Competitors

DARE vs. LONA, SPRO, TLPH, CLNN, and CING

How does Dare Bioscience compare to Athira Pharma?

Summary

How does Dare Bioscience compare to Spero Therapeutics?

Summary

How does Dare Bioscience compare to Talphera?

Summary

How does Dare Bioscience compare to Clene?

Summary

How does Dare Bioscience compare to Cingulate?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DARE vs. The Competition

Dare Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dare Bioscience (DARE) Competitors

DARE vs. LONA, SPRO, TLPH, CLNN, and CING

How does Dare Bioscience compare to Athira Pharma?

Is LONA or DARE more profitable?

Which has higher earnings & valuation, LONA or DARE?

Which has more risk & volatility, LONA or DARE?

Do analysts prefer LONA or DARE?

Do institutionals & insiders have more ownership in LONA or DARE?

Does the media prefer LONA or DARE?

Summary

How does Dare Bioscience compare to Spero Therapeutics?

Is DARE or SPRO more profitable?

Do analysts prefer DARE or SPRO?

Do institutionals and insiders believe in DARE or SPRO?

Which has better valuation & earnings, DARE or SPRO?

Does the media favor DARE or SPRO?

Which has more risk and volatility, DARE or SPRO?

Summary

How does Dare Bioscience compare to Talphera?

Is DARE or TLPH more profitable?

Do analysts recommend DARE or TLPH?

Which has higher earnings and valuation, DARE or TLPH?

Which has more risk and volatility, DARE or TLPH?

Does the media favor DARE or TLPH?

Do insiders & institutionals have more ownership in DARE or TLPH?

Summary

How does Dare Bioscience compare to Clene?

Do institutionals and insiders have more ownership in CLNN or DARE?

Which has more volatility and risk, CLNN or DARE?

Is CLNN or DARE more profitable?

Does the media prefer CLNN or DARE?

Do analysts recommend CLNN or DARE?

Which has preferable valuation & earnings, CLNN or DARE?

Summary

How does Dare Bioscience compare to Cingulate?

Do insiders and institutionals believe in DARE or CING?

Which has preferable valuation and earnings, DARE or CING?

Does the media favor DARE or CING?

Which has more risk & volatility, DARE or CING?

Do analysts prefer DARE or CING?

Is DARE or CING more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DARE vs. The Competition

Dare Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools